Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study by Wagner Lars M, Villablanca Judith G, Stewart Clinton F, Crews Kristine R, Groshen Susan, Reynolds C Patrick, Park Julie R, Maris John M, Hawkins Randall A, Daldrup-Link Heike E, Jackson Hollie A, Matthay Katherine K in Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PubMed

Abstract

Irinotecan and temozolomide have single-agent activity and schedule-dependent synergy against neuroblastoma. Because protracted administration of intravenous irinotecan is costly and inconvenient, we sought to determine the maximum-tolerated dose (MTD) of oral irinotecan combined with temozolomide in children with recurrent/resistant high-risk neuroblastoma.

[ hide abstract ]

Discussed In Paper